Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.36 |
| ▸ | OXTR | P30559 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7673942 | 0.78 | CYP2A6 (0.44) | CYP11B1CYP11B2NPC1RAB9ACYP3A4 | |
| SCHEMBL7682672 | 0.78 | KDM4E (0.43) | CYP3A4 | |
| SCHEMBL7680222 | 0.76 | CYP11B1 (0.43) | CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL7680376 | 0.70 | KDM4E (0.47) | CYP11B1CYP11B2RAB9ACYP3A4 | |
| SCHEMBL12973036 | 0.69 | HPGDS (0.60) | LDHAHPGDSCYP11B1CYP11B2BAZ2B | |
| SCHEMBL7681273 | 0.68 | NPC1 (0.51) | NPC1RAB9ACYP3A4 | |
| SCHEMBL7683109 | 0.68 | NPC1 (0.40) | NPC1RAB9ACYP3A4 | |
| SCHEMBL25118611 | 0.67 | HPGDS (0.58) | LDHAHPGDSCYP11B1CYP11B2BAZ2B | |
| SCHEMBL12523550 | 0.67 | HPGDS (0.58) | LDHAHPGDSCYP11B1CYP11B2BAZ2B | |
| SCHEMBL913315 | 0.67 | HPGDS (0.58) | LDHAHPGDSCYP11B1CYP11B2BAZ2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376490-B1 | STRONG N-METHYL-D-ASPARATE RECEPTOR ANTAGONISTS; USEFUL IN TREATING STROKES, ISCHEMIA, AND CENTRAL NERVOUS SYSTEM INJURIES | PFIZER INC | 2002-04-23 | — | — | US | claimed |
| EP-0885212-B1 | QUINOXALINEDIONES | PFIZER RES AND BR DEV COMPANY (IE) | 2001-11-14 | — | — | EP | claimed |
| JP-3110467-B2 | — | — | 2000-11-20 | — | — | JP | claimed |
| EP-0885212-A1 | QUINOXALINEDIONES | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-12-23 | — | — | EP | claimed |
| WO-1997032873-A1 | QUINOXALINEDIONES | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-09-12 | — | — | WO | claimed |
| US-6376490-B1 | STRONG N-METHYL-D-ASPARATE RECEPTOR ANTAGONISTS; USEFUL IN TREATING STROKES, ISCHEMIA, AND CENTRAL NERVOUS SYSTEM INJURIES | PFIZER INC | 2002-04-23 | — | — | US | disclosed |
| EP-0885212-B1 | QUINOXALINEDIONES | PFIZER RES AND BR DEV COMPANY (IE) | 2001-11-14 | — | — | EP | disclosed |
| EP-0885212-A1 | QUINOXALINEDIONES | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032873-A1 | QUINOXALINEDIONES | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-09-12 | — | — | WO | disclosed |